Exparel Injection, Suspension, Liposomal
NDC Package 65250-133-04

View Billable Units, 11-Digit Conversion Format, and RxNorm mappings
Table of Contents
    1. Package Information
    2. NDC HCPCS Crosswalk
    3. Other Packages
    4. Frequently Asked Questions

Package Information

Exparel (bupivacaine) injection is eXPAREL is indicated:In patients aged 6 years and older for single-dose infiltration to produce postsurgical local analgesiaIn adults as an interscalene brachial plexus nerve block to produce postsurgical regional analgesiaLimitations of UseSafety and efficacy have not been established in other nerve blocks. This formulation utilizes a injection, suspension, liposomal delivery system. Marketed by Pacira Pharmaceuticals, Inc., this product is identified by NDC 65250-133 and is authorized under FDA application NDA022496.

Identification & Billing

NDC Package Code
65250-133-04
Package Description
4 VIAL in 1 CARTON / 10 mL in 1 VIAL (65250-133-10)
Product Code
65250-133
11-Digit Billing Format
65250013304
Billing Unit
ML - Billing unit of "milliliter" is used when a product is measured by its liquid volume.
RxNorm Crosswalk

Clinical Specifications

Proprietary Name
Exparel
Non-Proprietary Name
Bupivacaine
Substance Name
Bupivacaine
Dosage Form
Injection, Suspension, Liposomal - A liquid preparation, suitable for injection, which consists of an oil phase dispersed throughout an aqueous phase in such a manner that liposomes (a lipid bilayer vesicle usually composed of phospholipids which is used to encapsulate an active drug substance, either within a lipid bilayer or in an aqueous space) are formed.
Administration Route
Infiltration - Administration that results in substances passing into tissue spaces or into cells.
Active Ingredient(s)
BUPIVACAINE 13.3 mg/mL
Pharmacologic Class
Usage Information
EXPAREL is indicated:In patients aged 6 years and older for single-dose infiltration to produce postsurgical local analgesiaIn adults as an interscalene brachial plexus nerve block to produce postsurgical regional analgesiaLimitations of UseSafety and efficacy have not been established in other nerve blocks.

Regulatory & Marketing

Labeler Name
Pacira Pharmaceuticals, Inc.
Product Type
Human Prescription Drug
FDA Application #
NDA022496
Marketing Category
NDA - A product marketed under an approved New Drug Application.
Start Marketing Date
01-01-2016
Listing Expiration
12-31-2026
Exclude Flag
N
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Billing & HCPCS Mapping

To facilitate insurance claims and reimbursement, this drug package is mapped to specific HCPCS administrative codes. This crosswalk aligns clinical data with the billing standards used in ASP (Average Sales Price), AWP, and OPPS payment systems. Use the cards below to identify the correct billable units for provider claims.

J0666
Source: PDAC
INJECTION, BUPIVACAINE LIPOSOME, 1 MG
HCPCS Dosage 1 MG
Units / Pkg

Note for Medical Coders: These mappings are synthesized from various CMS datasets including OPPS, PrEP, and DAC (Data Analysis and Coding) contractors. Always confirm unit conversions against the current quarter's pricing files before final submission.

* Please review the full disclaimer at the bottom of this page.

Other Available Packages

The following commercial packages are registered under the same Product NDC (65250-133). Click a package code to view its specific billing and regulatory data.

65250-133-09
10 VIAL in 1 CARTON / 10 mL in 1 VIAL (65250-133-10)

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 65250-133-04 identifies a specific commercial package of 4 vial in 1 carton / 10 ml in 1 vial (65250-133-10) of Exparel, a human prescription drug labeled by Pacira Pharmaceuticals, Inc.. This injection, suspension, liposomal is formulated for infiltration use and contains bupivacaine as the active substance.

Is this product currently listed with the FDA?

Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Pacira Pharmaceuticals, Inc. on January 01, 2016. The current certification is valid through December 31, 2026.

How is this Pacira Pharmaceuticals, Inc. product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 65250013304. Quantities are measured in per "ml or milliliter", products billed per milliliter are usually products measured by liquid volume.. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-3-2)
65250-133-04
11-Digit CMS (5-4-2)
65250-0133-04

Note: The zero is added to the Product segment to maintain the 5-4-2 structure.